Major Step Forward in Hansa Biopharma’s Imlifidase Clinical Study for Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), a trailblazer in enzyme technology aimed at tackling rare immunological diseases, has announced the completion…
Where health news comes full circle!